Ipratropium Teva

Ipratropium bromide, the active ingredient in Ipratropium Teva, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It is used to treat chronic obstructive pulmonary disease and asthma by relaxing airway smooth muscle and improving airflow.

GNH USA supplies Ipratropium Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium Teva is a bronchodilator that acts on the muscarinic receptors of the respiratory tract to relieve airway obstruction. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces dyspnea in patients with COPD. - Asthma: provides bronchodilation to relieve bronchospasm during acute episodes. - Chronic bronchitis: helps reduce airway resistance and improve breathing comfort.

Ipratropium bromide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough: irritation of the airway. - Throat irritation: discomfort in the throat. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty. - Angioedema: swelling of face, lips, or tongue. - Severe allergic reaction: rash, itching, or anaphylaxis. - Tachycardia: rapid heart rate. - Urinary retention: difficulty emptying the bladder. - Acute glaucoma: increased intra‑ocular pressure.

Before prescribing Ipratropium Teva, clinicians should consider several safety aspects. - Assess respiratory status: evaluate baseline lung function. - Use with caution in narrow‑angle glaucoma: may increase intra‑ocular pressure. - Monitor for urinary retention: especially in older males. - Avoid in patients with known hypersensitivity to ipratropium or formulation components. - Adjust dose in the elderly: start with the lowest effective dose. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ipratropium bromide can interact with other medications, altering its safety profile.

Major Interactions (Avoid): - Other anticholinergic agents: additive anticholinergic effects may increase risk of dry mouth, urinary retention, and glaucoma. - Ophthalmic anticholinergics: heightened risk of intra‑ocular pressure elevation. - Beta‑adrenergic agonists: may increase cardiovascular side effects when combined.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance anticholinergic burden. - Tricyclic antidepressants: increased risk of anticholinergic toxicity. - Phenothiazines: additive central anticholinergic effects. - Cholinesterase inhibitors: may reduce therapeutic efficacy of ipratropium. - Diuretics: monitor for electrolyte disturbances.